Evidence map›Paper›PMID 27120160›Full record

ArticleNature2016

Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.

Dominik Paquet, Dylan Kwart, Antonia Chen, Andrew Sproul, Samson Jacob, Shaun Teo, Kimberly Moore Olsen, Andrew Gregg, Scott Noggle, Marc Tessier-Lavigne

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 558 papers.

0numbers the graph read from it
0cells of the map it votes in
558citing papers in PubMed
59.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

558 citing papers in PubMed, 998 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. LFPM inhibition of RING1-mediated p53Cell death and differentiation · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

498 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dominik PaquetLaboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.
Dylan KwartLaboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.
Antonia ChenLaboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.
Andrew SproulThe New York Stem Cell Foundation Research Institute, New York, New York 10032, USA.
Samson JacobThe New York Stem Cell Foundation Research Institute, New York, New York 10032, USA.
Shaun TeoLaboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.
Kimberly Moore OlsenLaboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.
Andrew GreggLaboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.
Scott NoggleThe New York Stem Cell Foundation Research Institute, New York, New York 10032, USA.
Marc Tessier-LavigneLaboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.
Rockefeller University · USNew York Stem Cell Foundation · US

Funding

Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Transforming Translational Science and Education to Benefit Human HealthUL1TR000043 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$26.8M
Howard Hughes Medical InstituteNCATS NIH HHS 8 UL1 TR000043NIGMS NIH HHS T32GM007739
6 · The paper itself

Abstract

The bacterial CRISPR/Cas9 system allows sequence-specific gene editing in many organisms and holds promise as a tool to generate models of human diseases, for example, in human pluripotent stem cells. CRISPR/Cas9 introduces targeted double-stranded breaks (DSBs) with high efficiency, which are typically repaired by non-homologous end-joining (NHEJ) resulting in nonspecific insertions, deletions or other mutations (indels). DSBs may also be repaired by homology-directed repair (HDR) using a DNA repair template, such as an introduced single-stranded oligo DNA nucleotide (ssODN), allowing knock-in of specific mutations. Although CRISPR/Cas9 is used extensively to engineer gene knockouts through NHEJ, editing by HDR remains inefficient and can be corrupted by additional indels, preventing its widespread use for modelling genetic disorders through introducing disease-associated mutations. Furthermore, targeted mutational knock-in at single alleles to model diseases caused by heterozygous mutations has not been reported. Here we describe a CRISPR/Cas9-based genome-editing framework that allows selective introduction of mono- and bi-allelic sequence changes with high efficiency and accuracy. We show that HDR accuracy is increased dramatically by incorporating silent CRISPR/Cas-blocking mutations along with pathogenic mutations, and establish a method termed 'CORRECT' for scarless genome editing. By characterizing and exploiting a stereotyped inverse relationship between a mutation's incorporation rate and its distance to the DSB, we achieve predictable control of zygosity. Homozygous introduction requires a guide RNA targeting close to the intended mutation, whereas heterozygous introduction can be accomplished by distance-dependent suboptimal mutation incorporation or by use of mixed repair templates. Using this approach, we generated human induced pluripotent stem cells with heterozygous and homozygous dominant early onset Alzheimer's disease-causing mutations in amyloid precursor protein (APP(Swe)) and presenilin 1 (PSEN1(M146V)) and derived cortical neurons, which displayed genotype-dependent disease-associated phenotypes. Our findings enable efficient introduction of specific sequence changes with CRISPR/Cas9, facilitating study of human disease.

Indexed as

HeterozygoteHomozygoteAdolescentAge of OnsetAllelesAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsBase SequenceCRISPR-Cas SystemsDNA Breaks, Double-StrandedDNA CleavageDNA RepairFemaleGenes, DominantGenetic Association StudiesAmyloid beta-Protein PrecursorPresenilinsRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID27120160
OpenAlexW2343876552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.